Laura Blaikie

Project Title: Synthesis and Evaluation of Multi-Target Compounds for the Treatment of Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common neurodegenerative disease, and is among the leading causes of death worldwide.  Although there are clinical drugs available to manage the condition and reduce the associated symptoms, no curative drugs currently exist and hence it remains a huge unmet medical need worldwide.  With an ageing world population and increased life expectancy, the prevalence of age related diseases is rapidly increasing.  It is estimated that the total number of AD patients globally will rise to well over 100 million by 2050, thus causing a huge financial burden for the health care system.  Therefore, there is an urgent need for new drugs to treat and manage neurodegenerative diseases, including AD.  Since the onset and progression of AD is due to many biological mechanisms, treatment with more than one drug is often required.  This project aims to create novel molecules that have the ability to act at several targets implicated in the development of the disease.  It can be expected that these drugs will compensate for or restore the lost cognitive functions, as well as suppress further development of the neurodegenerative process in AD.  These include the combinational approaches where a single molecule exhibits its inhibitory properties.

Awarded: Carnegie PhD Scholarship

Field: Pharmacy

University: Robert Gordon University

Latest News